| Dr Jessica L Goldberger, MD | |
|
2741 Debarr Rd Ste C-205, Anchorage, AK 99508-2961 | |
| (907) 279-4307 | |
| (907) 258-7782 |
| Full Name | Dr Jessica L Goldberger |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 9 Years |
| Location | 2741 Debarr Rd Ste C-205, Anchorage, Alaska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659766582 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 144569 (Alaska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Kodiak Island Medical Ctr | Kodiak, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Womens Care Of Alaska Pc | 8921091091 | 9 |
News Archive
"Unchecked environmental destruction will halt - or even reverse - the huge improvements seen in the living conditions of the world's poorest people in recent decades," the United Nations Development Programme (UNDP) warns in its 2011 Human Development report, which was released on Wednesday, the Guardian reports.
Biogen Idec and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed to evaluate switching to TYSABRI® (natalizumab) from Copaxone® (glatiramer acetate) or Rebif® (interferon beta-1a) in patients with relapsing remitting multiple sclerosis.
PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it has secured exclusive rights to two issued U.S. patents from Hospital for Special Surgery, New York. PIKAMAB is developing Lupus TherasightTM, a novel theragnostic product that will eventually help guide the drug development process and patient treatment protocols in the areas of lupus and lupus nephritis.
Florida-based biopharmaceutical company Oragenics, Inc. announced today that its oral care probiotic EvoraPlus® is now expected to be available at corporate-owned GNC stores nationwide. In addition, GNC has included Oragenics' oral care probiotic for children, EvoraKids™, in its concept stores and on GNC.com.
› Verified 1 days ago
| Entity Name | Providence Health & Services Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952430902 PECOS PAC ID: 5799675120 Enrollment ID: O20040318000605 |
News Archive
"Unchecked environmental destruction will halt - or even reverse - the huge improvements seen in the living conditions of the world's poorest people in recent decades," the United Nations Development Programme (UNDP) warns in its 2011 Human Development report, which was released on Wednesday, the Guardian reports.
Biogen Idec and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed to evaluate switching to TYSABRI® (natalizumab) from Copaxone® (glatiramer acetate) or Rebif® (interferon beta-1a) in patients with relapsing remitting multiple sclerosis.
PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it has secured exclusive rights to two issued U.S. patents from Hospital for Special Surgery, New York. PIKAMAB is developing Lupus TherasightTM, a novel theragnostic product that will eventually help guide the drug development process and patient treatment protocols in the areas of lupus and lupus nephritis.
Florida-based biopharmaceutical company Oragenics, Inc. announced today that its oral care probiotic EvoraPlus® is now expected to be available at corporate-owned GNC stores nationwide. In addition, GNC has included Oragenics' oral care probiotic for children, EvoraKids™, in its concept stores and on GNC.com.
› Verified 1 days ago
| Entity Name | Womens Care Of Alaska Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174702468 PECOS PAC ID: 8921091091 Enrollment ID: O20040405001520 |
News Archive
"Unchecked environmental destruction will halt - or even reverse - the huge improvements seen in the living conditions of the world's poorest people in recent decades," the United Nations Development Programme (UNDP) warns in its 2011 Human Development report, which was released on Wednesday, the Guardian reports.
Biogen Idec and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed to evaluate switching to TYSABRI® (natalizumab) from Copaxone® (glatiramer acetate) or Rebif® (interferon beta-1a) in patients with relapsing remitting multiple sclerosis.
PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it has secured exclusive rights to two issued U.S. patents from Hospital for Special Surgery, New York. PIKAMAB is developing Lupus TherasightTM, a novel theragnostic product that will eventually help guide the drug development process and patient treatment protocols in the areas of lupus and lupus nephritis.
Florida-based biopharmaceutical company Oragenics, Inc. announced today that its oral care probiotic EvoraPlus® is now expected to be available at corporate-owned GNC stores nationwide. In addition, GNC has included Oragenics' oral care probiotic for children, EvoraKids™, in its concept stores and on GNC.com.
› Verified 1 days ago
| Entity Name | Anchorage Women's Clinic At Providence Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265496061 PECOS PAC ID: 9032102124 Enrollment ID: O20040405001651 |
News Archive
"Unchecked environmental destruction will halt - or even reverse - the huge improvements seen in the living conditions of the world's poorest people in recent decades," the United Nations Development Programme (UNDP) warns in its 2011 Human Development report, which was released on Wednesday, the Guardian reports.
Biogen Idec and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed to evaluate switching to TYSABRI® (natalizumab) from Copaxone® (glatiramer acetate) or Rebif® (interferon beta-1a) in patients with relapsing remitting multiple sclerosis.
PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it has secured exclusive rights to two issued U.S. patents from Hospital for Special Surgery, New York. PIKAMAB is developing Lupus TherasightTM, a novel theragnostic product that will eventually help guide the drug development process and patient treatment protocols in the areas of lupus and lupus nephritis.
Florida-based biopharmaceutical company Oragenics, Inc. announced today that its oral care probiotic EvoraPlus® is now expected to be available at corporate-owned GNC stores nationwide. In addition, GNC has included Oragenics' oral care probiotic for children, EvoraKids™, in its concept stores and on GNC.com.
› Verified 1 days ago
| Entity Name | Obhg Alaska Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740697069 PECOS PAC ID: 7113233834 Enrollment ID: O20150826000621 |
News Archive
"Unchecked environmental destruction will halt - or even reverse - the huge improvements seen in the living conditions of the world's poorest people in recent decades," the United Nations Development Programme (UNDP) warns in its 2011 Human Development report, which was released on Wednesday, the Guardian reports.
Biogen Idec and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed to evaluate switching to TYSABRI® (natalizumab) from Copaxone® (glatiramer acetate) or Rebif® (interferon beta-1a) in patients with relapsing remitting multiple sclerosis.
PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it has secured exclusive rights to two issued U.S. patents from Hospital for Special Surgery, New York. PIKAMAB is developing Lupus TherasightTM, a novel theragnostic product that will eventually help guide the drug development process and patient treatment protocols in the areas of lupus and lupus nephritis.
Florida-based biopharmaceutical company Oragenics, Inc. announced today that its oral care probiotic EvoraPlus® is now expected to be available at corporate-owned GNC stores nationwide. In addition, GNC has included Oragenics' oral care probiotic for children, EvoraKids™, in its concept stores and on GNC.com.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jessica L Goldberger, MD 2741 Debarr Rd Ste C-205, Anchorage, AK 99508-2961 Ph: () - | Dr Jessica L Goldberger, MD 2741 Debarr Rd Ste C-205, Anchorage, AK 99508-2961 Ph: (907) 279-4307 |
News Archive
"Unchecked environmental destruction will halt - or even reverse - the huge improvements seen in the living conditions of the world's poorest people in recent decades," the United Nations Development Programme (UNDP) warns in its 2011 Human Development report, which was released on Wednesday, the Guardian reports.
Biogen Idec and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed to evaluate switching to TYSABRI® (natalizumab) from Copaxone® (glatiramer acetate) or Rebif® (interferon beta-1a) in patients with relapsing remitting multiple sclerosis.
PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it has secured exclusive rights to two issued U.S. patents from Hospital for Special Surgery, New York. PIKAMAB is developing Lupus TherasightTM, a novel theragnostic product that will eventually help guide the drug development process and patient treatment protocols in the areas of lupus and lupus nephritis.
Florida-based biopharmaceutical company Oragenics, Inc. announced today that its oral care probiotic EvoraPlus® is now expected to be available at corporate-owned GNC stores nationwide. In addition, GNC has included Oragenics' oral care probiotic for children, EvoraKids™, in its concept stores and on GNC.com.
› Verified 1 days ago
Dr. Wendy Sue Cruz, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2741 Debarr Rd Ste C205, Anchorage, AK 99508 Phone: 907-279-2273 Fax: 907-258-7705 | |
Dr. James Thomas Barber Jr., D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3831 Piper St Ste Sll020, Anchorage, AK 99508 Phone: 907-212-3470 Fax: 907-212-3474 | |
Dr. Natalie Dawn Ward, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3260 Providence Dr, Ste. #425, Anchorage, AK 99508 Phone: 907-561-7111 Fax: 907-770-7891 | |
Tania H Hall, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3260 Providence Dr, Ste 322, Anchorage, AK 99508 Phone: 907-563-5151 Fax: 907-563-6278 | |
Anne Gray, Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 4141 Ambassador Dr, Anchorage, AK 99508 Phone: 907-729-1542 | |
Mrs. Kristin M Murray, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 4115 Lake Otis Pkwy, Anchorage, AK 99508 Phone: 907-563-7228 Fax: 907-563-6278 | |
Kathryn Murphy, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4320 Diplomacy Dr, Anchorage, AK 99508 Phone: 907-729-3116 |